FARMINGTON, Conn. (PRWEB)
November 09, 2020
CytoVeris Inc., an emerging company formed with the vision to change the paradigm in cancer surgery through the introduction of optical-based “guided surgical tools”, today announced the appointment of Dr. Michael Fenn, Ph.D., Harvard University, as the newest member of its Scientific Advisory Board (SAB). Dr. Fenn serves as the Director of Healthcare and Life Sciences at the Harvard Innovation Labs. He is a biomedical engineer, entrepreneur and startup advisor working within the Harvard innovation and entrepreneur ecosystem. Dr. Fenn brings to CytoVeris significant knowledge and expertise in Raman spectroscopy, machine learning, and clinical translation of medical devices.
“Our SAB brings a broad range of expertise and knowledge that is critical to CytoVeris’ product design and clinical translation plans, and we are thrilled to have Michael, an accomplished scientific professional augment our interdisciplinary team in advancing our devices and realizing our mission,” said Dr. Alan Kersey, President and CEO of CytoVeris.
The other members of the SAB include Professor José Costa, Professor Emeritus of Pathology at Yale University School of Medicine, Dr. John Moon, Distinguished Scientist and Vice President at Illumina, and Professor Ishan Barman of Johns Hopkins University.
“The CytoVeris SAB provides invaluable guidance and direction to pursue our mission of disrupting the current paradigm of breast cancer surgery and improve lives of cancer patients,” commented Dr. Rishikesh Pandey, Chief Scientist. “Our SAB is comprised of prominent and pioneering scientific and medical experts, and we are privileged to welcome Dr. Fenn to this esteemed group.”
Through the introduction of optical “guided surgical tools” that allow for the real-time detection of cancer in an intraoperative setting, CytoVeris is on a mission to change the current paradigm in cancer surgery – ensuring surgeons can remove all cancer in a single surgical procedure. CytoVeris is leveraging the convergence of powerful optical technologies, knowledge of biochemical alteration during carcinogenesis, and explainable artificial intelligence to bring new capabilities into the hands of surgeons, and drive improvements in patient outcomes. We are driven by a passion for science and compassion for cancer patients. For more information, please visit: https://www.cytoveris.com
Share article on social media or email: